Stocks Settle Higher on Hopes of Accelerated Fed Rate Cuts

US equities advanced on Tuesday, primarily driven by a significant downward revision to US payrolls, which bolstered market expectations for accelerated Fed interest rate cuts, now fully pricing in a 25bp cut next week and anticipating a total of 72bps by year-end. Robust M&A activity, notably Anglo American's acquisition of Teck Resources and Novartis's purchase of Tourmaline Bio, also underpinned the gains. While Treasury yields edged higher due to equity strength and supply, the dovish payroll data provided some support, with ongoing tariff debates and upcoming inflation data poised to influence market sentiment.

Analysis

U.S. equity indices posted modest gains, with the S&P 500 rising 0.27%, driven primarily by macroeconomic signals that bolster the case for a more accommodative Federal Reserve. A preliminary revision to U.S. payrolls revealed 911,000 fewer jobs than previously reported through March, a historically large downward adjustment that suggests a weaker labor market and has solidified market expectations for a 25 bp rate cut at the next FOMC meeting. Notably, the market is now pricing in a 10% chance of a 50 bp cut, up from zero, and a 75% probability of a subsequent cut in October. This dovish sentiment overshadowed a 3.0 bp rise in the 10-year Treasury yield to 4.070%, which was influenced by equity strength and upcoming debt supply. Corporate activity also provided a tailwind, highlighted by Novartis's $1.4 billion acquisition of Tourmaline Bio (TRML), which sent its stock soaring over 57%, and takeover talks driving Brighthouse Financial (BHF) up 12%. Sector performance was highly divergent; health insurers saw UnitedHealth (UNH) surge 8% on a positive outlook for Medicare Advantage ratings, while Humana (HUM) plummeted 12% on fears of the opposite, demonstrating significant idiosyncratic risk within the sector. Conversely, commodity-linked stocks like Albemarle (ALB) and Freeport-McMoRan (FCX) fell sharply by 11% and 5% respectively due to specific supply-side news and operational suspensions, while homebuilders retreated on profit-taking.

Key Decisions for Investors

• Given the market's pricing of accelerated Fed rate cuts, investors should assess increasing exposure to rate-sensitive growth stocks, while closely monitoring upcoming CPI and PPI releases which could challenge this dovish narrative.
• The profound divergence between UnitedHealth's rally and Humana's decline on Medicare rating news necessitates a granular, stock-specific approach to the health insurance sector, focusing on companies best positioned to navigate regulatory payment adjustments.
• The sharp sell-off in commodity stocks like Albemarle and the profit-taking in homebuilders serve as a caution; it is prudent to manage risk in highly appreciated or volatile cyclical sectors that are sensitive to supply-side news and operational updates.
• While active M&A provides event-driven opportunities in names like Tourmaline Bio and Brighthouse Financial, the unresolved tariff legal battle remains a significant macro overhang that could justify hedging strategies for portfolios sensitive to global trade disruptions.